Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/23347
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorHensel, Kai-
dc.contributor.authorRendón Londoño, Julio César-
dc.contributor.authorNavas Navas, María Cristina-
dc.contributor.authorRots, Marianne-
dc.contributor.authorPostberg, Jan-
dc.date.accessioned2021-10-21T15:53:13Z-
dc.date.available2021-10-21T15:53:13Z-
dc.date.issued2017-
dc.identifier.issn1742-464X-
dc.identifier.issn10.1111/febs.14094-
dc.identifier.urihttp://hdl.handle.net/10495/23347-
dc.description.abstractABSTRACT: Worldwide, chronic hepatitis B virus (HBV) infection is a major health problem and no cure exists. Importantly, hepatocyte intrusion by HBV particles results in a complex deregulation of both viral and host cellular genetic and epigenetic processes. Among the attempts to develop novel therapeutic approaches against HBV infection, several options targeting the epigenomic regulation of HBV replication are gaining attention. These include the experimental treatment with ‘epidrugs’. Moreover, as a targeted approach, the principle of ‘epigenetic editing’ recently is being exploited to control viral replication. Silencing of HBV by specific rewriting of epigenetic marks might diminish viral replication, viremia, and infectivity, even- tually controlling the disease and its complications. Additionally, epigenetic editing can be used as an experimental tool to increase our limited understanding regarding the role of epigenetic modifications in viral infections. Aiming for permanent epigenetic reprogramming of the viral genome without unspecific side effects, this breakthrough may pave the roads for an ambitious technological pursuit: to start designing a curative approach utilizing manipulative molecular therapies for viral infections in vivo.spa
dc.format.extent23spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherWileyspa
dc.publisherFederation of European Biochemical Societiesspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleVirus–host interplay in hepatitis B virus infection and epigenetic treatment strategiesspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo de Gastrohepatologíaspa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1742-4658-
oaire.citationtitleThe Febs Journalspa
oaire.citationstartpage3550spa
oaire.citationendpage3572spa
oaire.citationissue284spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.publisher.placeOxford, Inglaterraspa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTREVspa
dc.type.localArtículo de revisiónspa
dc.subject.decsSistemas CRISPR-Cas-
dc.subject.decsCRISPR-Cas Systems-
dc.subject.decsMetilación de ADN-
dc.subject.decsDNA Methylation-
dc.subject.decsEpigenoma-
dc.subject.decsEpigenome-
dc.subject.decsVirus de la Hepatitis B-
dc.subject.decsHepatitis B virus-
dc.description.researchgroupidCOL0024159spa
dc.relation.ispartofjournalabbrevFEBS. J.spa
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
JulioRendon_2017_VirusInfectionStrategies.pdfArtículo de revisión1.11 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons